Faron Pharmaceuticals Feed

	Tid*
2025-08-27	08:00	Kvartalsrapport 2025-Q2
2025-03-21	N/A	Årsstämma
2025-02-27	08:00	Bokslutskommuniké 2024
2024-08-28	-	Kvartalsrapport 2024-Q2
2024-03-25	-	X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22	-	Årsstämma
2024-03-14	-	Bokslutskommuniké 2023
2023-08-29	-	Kvartalsrapport 2023-Q2
2023-03-27	-	X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24	-	Årsstämma
2023-03-03	-	Bokslutskommuniké 2022
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-07-07	-	Extra Bolagsstämma 2022
2022-04-25	-	X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22	-	Årsstämma
2022-03-25	-	Bokslutskommuniké 2021
2021-08-26	-	Kvartalsrapport 2021-Q2
2021-04-26	-	X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23	-	Årsstämma
2021-03-25	-	Bokslutskommuniké 2020
2020-05-14	-	X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13	-	Årsstämma
2020-03-20	-	Bokslutskommuniké 2019

Land	Finland
Lista	First North Finland
Sektor	Hälsovård
Industri	Bioteknik

2025-01-31 08:00:00 Final Patient Identified for the BEXMAB Study 2,04 EUR | -3,33% | 0,73 MEUR

2024-12-13 08:00:02 Faron’s Financial Calendar for 2025 2,04 EUR | +2,45% | 0,33 MEUR

2024-12-10 08:00:07 Faron presents BEXMAB data at ASH Annual Meeting 2,24 EUR | -4,68% | 1,18 MEUR

2024-12-02 09:00:00 Interactions with UK Regulatory Authorities 2,25 EUR | +10,57% | 1,00 MEUR

2024-11-27 08:00:10 Positive Phase 2 Interim Results from BEXMAB Trial 2,14 EUR | +10,88% | 1,11 MEUR

2024-11-11 08:00:10 Targeting Soluble Clever-1 for Autoimmune Diseases 1,93 EUR | +1,26% | 0,72 MEUR

2024-11-05 08:00:03 Shareholders’ Nomination Board 1,86 EUR | -1,17% | 0,38 MEUR

2024-10-22 08:00:03 Faron’s Capital Markets Day 2024 2,16 EUR | -12,37% | 1,99 MEUR

2024-10-07 08:00:09 Faron announces Capital Markets Day 2,68 EUR | +2,88% | 0,40 MEUR

2024-08-30 08:00:14 Grant of options 2,46 EUR | -1,40% | 0,54 MEUR

2024-08-27 08:00:12 Faron 2024 Half-Year Financial Results 2,70 EUR | +14,65% | 2,24 MEUR

2024-08-27 08:00:12 FDA Grants Fast Track Designation for Bexmarilimab 2,70 EUR | +14,65% | 2,24 MEUR

2024-08-20 08:00:17 Notice of Half-Year Financial Results 2,00 EUR | -2,91% | 0,30 MEUR

2024-08-13 08:00:12 Traumakine Research Collaboration and DoD Grant 2,21 EUR | +1,84% | 0,42 MEUR

2024-08-08 08:00:13 Appointment of Chief Financial Officer 2,13 EUR | +7,58% | 0,65 MEUR

2024-08-07 11:00:00 Grant of options 1,98 EUR | +1,96% | 0,21 MEUR

2024-08-06 09:30:00 Faron Appoints Dr. Petri Bono as new CMO 1,94 EUR | +6,24% | 0,52 MEUR

2024-07-11 08:00:07 Faron Announces Positive FDA Feedback 1,58 EUR | +29,18% | 1,80 MEUR

2024-06-25 15:00:00 Update on settlement 1,18 EUR | +4,63% | 0,57 MEUR

2024-06-25 11:30:01 Holding(s) in Company - Replacement 1,18 EUR | +4,63% | 0,57 MEUR

2024-06-24 13:45:01 Holding(s) in Company 1,12 EUR | -1,40% | 0,83 MEUR

2024-06-20 14:00:00 New shares registered with Finnish Trade Register 1,14 EUR | +8,16% | 19,2 MEUR

2024-06-20 08:00:08 Fully subscribed EUR 30.7 million share offering 1,14 EUR | +8,16% | 19,2 MEUR

2024-06-05 09:00:00 Proposed REX Retail Offer 1,28 EUR | -2,74% | 1,09 MEUR

2024-06-04 08:00:00 Faron commences a share offering 1,31 EUR | -44,20% | 2,52 MEUR

2024-05-20 09:00:00 Faron Pharmaceuticals julkaisi ensimmäisiä faasin II tuloksia leukemiapotilailla 3,10 EUR | +7,08% | 1,82 MEUR

2024-05-20 08:00:00 Initial positive data from Phase 2 of BEXMAB 3,10 EUR | +7,08% | 1,82 MEUR

2024-05-17 17:00:00 Issuance of warrants

2024-05-16 08:05:00 Founders named European Inventor Award finalists 2,85 EUR | +1,79% | 0,53 MEUR

2024-05-13 08:00:00 Replacement – Board Change 2,41 EUR | -5,68% | 1,27 MEUR

2024-04-30 15:00:00 Update on financial status 1,81 EUR | +2,84% | 0,16 MEUR

2024-04-30 14:00:00 Board Change 1,81 EUR | +2,84% | 0,16 MEUR

2024-04-16 08:00:00 Faron confirms plans under new leadership 1,48 EUR | +2,21% | 0,20 MEUR

2024-04-15 08:00:00 Appointment of Chief Financial Officer 1,45 EUR | +0,84% | 0,09 MEUR

2024-04-08 08:10:00 Approval of Warrant Terms and Conditions 1,52 EUR | 0,00% | 0,12 MEUR

2024-04-08 08:05:00 Decisions of the Board of Directors 1,52 EUR | 0,00% | 0,12 MEUR

2024-04-08 08:00:00 Appointment of Chief Executive Officer 1,52 EUR | 0,00% | 0,12 MEUR

2024-04-05 13:00:00 Results of the Annual General Meeting 1,52 EUR | -2,07% | 0,07 MEUR

2024-04-04 08:00:00 Announcement of Placing 1,55 EUR | -8,40% | 5,26 MEUR

2024-03-28 08:00:00 Issue of Warrants to IPF Funding Update 1,71 EUR | +2,51% | 0,11 MEUR

2024-03-26 11:00:00 Faron´s Annual Report 2023 1,70 EUR | -0,35% | 0,10 MEUR

2024-03-18 10:08:20 Faron Pharmaceuticals julkaisee jälleen rohkaisevia testituloksia verisyöpien hoidossa 2,15 EUR | +20,51% | 0,42 MEUR

2024-03-18 08:00:00 Additional Positive Data from Phase 1 of BEXMAB 2,15 EUR | +20,51% | 0,42 MEUR

2024-03-14 08:00:00 Faron to Host BEXMAB Webcast 1,72 EUR | -7,14% | 0,09 MEUR

2024-03-13 15:00:00 Notice of Annual General Meeting 2024 1,85 EUR | +13,37% | 0,14 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Faron Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Faron Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden